Macomics is an immuno-oncology company with world-leading expertise in macrophage biology. We are focused on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defense against tumors.
Mandeville Technology Limited provides flexible chief financial officer or finance director services to healthcare and technology companies. Services in the following areas are available: accounting, including audit preparation, financial reporting and management accounts; company secretarial; corporate finance, including deal structuring, disposals, equity funding, financial modelling, mergers and acquisitions, valuations and venture debt; corporate and financial strategy, including budgeting and forecasting, business and financial advice and corporate restructuring; employee incentive schemes, including EMI share options, employee benefit trusts and share purchase schemes; non-executive director; and taxation, including: EIS, R&D tax credits and VAT.
Marks & Clerk has long been recognised as one of the leading patent, trade mark attorney and intellectual property law firms across the globe, with eight offices across the UK and a further eight in North America and the Asia-Pacific. We offer a comprehensive range of intellectual property services – covering patents, trade marks, designs and copyright. This includes obtaining protection worldwide, portfolio management, strategic and commercial advice, licensing and other contracts, enforcement, due diligence and litigation. . Renowned for our client-led approach, we are a top-tier firm, noted by Legal 500 for our life sciences practitioners and ‘strength in depth.’ From the capture and exploitation of an idea, to the enforcement or defence of rights in disputes Marks & Clerk is your expert partner to ensure your IP is protected and fully exploited. Today’s local is tomorrow’s global – and with our diverse team of practitioners, you’re always supported by a network of experts.
Ranked Tier 1 in Legal 500, Mathys & Squire is one of Europe's most highly regarded intellectual property firms. Founded in 1910, we have over 100 years of experience in the protection and commercialisation of intellectual property rights, leading the field with insight, innovation and quality.
With more than 60 qualified attorneys and offices in London, Manchester, Cambridge, Brighton, Oxford, York, the Midlands, Paris, Munich, Luxembourg and a team in China, we use a combination of our expertise, innovation and creativity to become part of our clients’ success stories and empower our teams to go above and beyond what clients expect when it comes to service delivery.
Mathys & Squire is pleased to offer One Nucleus members discounted rates for providing intellectual property support. Contact Dr Craig Titmus CTitmus@mathys-squire.com for more information.
Maxion Therapeutics Limited is a newly founded drug discovery company generating antibody-like therapeutics to target ion channel-driven diseases. A number of untreatable diseases such as chronic pain, autoimmune disorders and heart diseases involve ion channel dysfunction. Antibody drugs represent a potential solution but despite significant research spending clinical approval of this type of drug has not been achieved to date due to significant technical challenges. Maxion is addressing this unmet medical need with its proprietary Knotbody technology. wherein venom-derived cysteine-rich peptides (knottins) are fused into the surface of antibodies thereby combining the best features of both molecules.
Consultancy on strategy, business development, fund-raising and general commercial matters in Life Sciences, particularly biotech.
Mestag Therapeutics was established in 2020 to develop impactful new medicines for people affected by cancer and inflammatory disease. Recent data point to a type of cells called fibroblasts as being important in driving the disease process. Our mission is to lead the field in discovering, developing and delivering impactful precision medicines through unparalleled insight into disease-driving fibroblast sub-populations.